Recent advance in phytonanomedicine and mineral nanomedicine delivery system of the treatment for acute myeloid leukemia

Abstract

Acute myeloid leukemia (AML) is an invasive hematopoietic malignancy caused by excessive proliferation of myeloblasts. Classical chemotherapies and cell transplantation therapies have remarkable efficacy in AML treatment; however, 30–40% of patients relapsed or had refractory disease. The resistance of AML is closely related to its inherent cytogenetics or various gene mutations. Recently, phytonanomedicine are found to be effective against resistant AML cells and have become a research focus for nanotechnology development to improve their properties, such as increasing solubility, improving absorption, enhancing bioavailability, and maintaining sustained release and targeting. These novel phytonanomedicine and mineral nanomedicine, including nanocrystals, nanoemulsion, nanoparticles, nanoliposome, and nanomicelles, offer many advantages, such as flexible dosages or forms, multiple routes of administration, and curative effects. Therefore, we reviewed the application and progress of phytomedicine in AML treatment and discussed the limitations and future prospects. This review may provide a solid reference to guide future research on AML treatment.

Therapeutic Implications of Dietary Polyphenols-Loaded Nanoemulsions in Cancer Therapy

“…NEs, because of their versatile characteristic features, have been a preferred choice of researchers in treating several types of cancer including colorectal, breast, ovarian, lung, brain, leukemia, prostate, and melanoma . NEs ranging in size from 20 to 100 nm can get encapsulated and accumulate in tumor tissues (Figure ) because they are both large enough to evade rapid renal clearance and small enough to flow through blood arteries .…”

“…35 The properties of NEs such as greater surface area, modifiable surface charge, higher circulation half-life, precise targeting, and formulation imaging capability that are necessary to create an effective therapeutic impact have drawn increased attention in the field of cancer therapy research. 45 NEs, because of their versatile characteristic features, have been a preferred choice of researchers in treating several types of cancer including colorectal, 46 breast, 47 ovarian, 48 lung, 49 brain, 50 leukemia, 51 prostate, 52 and melanoma. 53 NEs ranging in size from 20 to 100 nm can get encapsulated and accumulate in tumor tissues (Figure 2) because they are both large enough to evade rapid renal clearance and small enough to flow through blood arteries.…”

The clinical regimens and cell membrane camouflaged nanodrug delivery systems in hematologic malignancies treatment

“…Frontiers in Pharmacology frontiersin.org developed to carry anti-HMs drugs reaching HMs lesions with focused accumulation, controlled drug release, and low side effects (Jia et al, 2023). Among nanocarriers, liposome is the U.S. Food and Drug Administration (FDA)-approved nanocarrier for drug delivery against HMs (Hani et al, 2023).…”

“…The inherent physical and chemical properties of drugs including poor solubility, low stability, and no targeting ability, lead to side effects on normal tissues in the body, often limiting their therapeutic effect in clinical application ( Halwani, 2022 ). Various nanocarriers have been developed to carry anti-HMs drugs reaching HMs lesions with focused accumulation, controlled drug release, and low side effects ( Jia et al, 2023 ). Among nanocarriers, liposome is the U.S. Food and Drug Administration (FDA)-approved nanocarrier for drug delivery against HMs ( Hani et al, 2023 ).…”